Kenneth W. Locke
Keine laufenden Positionen mehr
Profil
Kenneth W.
Locke worked as a Manager-Behavioral Neuroscience at Indevus Pharmaceuticals, Inc. from 1989 to 2013.
He was also the Chief Business & Scientific Officer at MediciNova, Inc. from 2000 to 2008, and the Vice President-Research at Tanabe Research Laboratories U.S.A., Inc. He served as the Head-Analgesics at Hoechst-Roussel Pharmaceuticals, Inc. from 2011 to 2013.
From 2008 to 2016, he was the Chief Scientific Officer at Neothetics, Inc. Dr. Locke received his undergraduate degree from Franklin & Marshall College and his graduate and doctorate degrees from Emory University School of Medicine.
Ehemalige bekannte Positionen von Kenneth W. Locke
| Unternehmen | Position | Ende |
|---|---|---|
Neothetics, Inc.
 Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2016 |
| MEDICINOVA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 30.04.2008 |
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Tanabe Research Laboratories U.S.A., Inc.
 Tanabe Research Laboratories U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Part of Mitsubishi Chemical Group Corp., Tanabe Research Laboratories U.S.A., Inc. develops pharmaceutical products. The company is based in San Diego, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
| Hoechst-Roussel Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Ausbildung von Kenneth W. Locke
| Franklin & Marshall College | Undergraduate Degree |
| Emory University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MEDICINOVA, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
| Hoechst-Roussel Pharmaceuticals, Inc. | |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | Health Technology |
Tanabe Research Laboratories U.S.A., Inc.
Tanabe Research Laboratories U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Part of Mitsubishi Chemical Group Corp., Tanabe Research Laboratories U.S.A., Inc. develops pharmaceutical products. The company is based in San Diego, CA. | Health Technology |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
